Because of their involvement in all major human diseases, protein kinases have become a major screening target in the pharmaceutical industry. 1 Cyclin-dependent kinases (CDKs) constitute a family of highly conserved protein kinases targeted for the therapy of cancer, viral infections and neurodegenerative diseases. Glycogen synthase kinases (GSK-3) play a key role in neurodegenerative disorders (Alzheimer's disease), diabetes and cardiovascular diseases. These families of kinases have thus been extensively used as targets to identify small molecularweight pharmacological inhibitors of potential therapeutic interest. 2,3 Among these inhibitors, the bisindole indirubin and its analogs have raised considerable interest, since they were discovered to inhibit CDKs and GSK-3. 4 Following our search for GSK-3 inhibitors of potential therapeutic interest, we previously identified a series of novel 5-substituted indirubins. 5 These bis-indole indigoids were synthesized in good yields by the condensation of isatins with indoxyl acetate in the presence of Na2CO3.
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We report herein on the structural characterization of one of them, i.e. the (2'Z)-5-acetamidoindirubin (Fig. 1) , which exhibited inhibitory activity in a submicromolar range against CDK1 and CDK5 (IC50 = 0.05 and 0.018 mM, respectively), and showed low nanomolar inhibition of GSK-3 (IC50 = 7.5 nM). In addition to the previous published crystal structure of CDKs in complex with indirubin derivatives, 6 the present crystal structure determination could now be used to clarify the X-ray Structure Analysis Online Dark purple crystals suitable for X-ray analysis were obtained by slow crystallization from a dichloromethane-methanol solution at +20˚C. The molecular structure of (2'Z)-5-acetamidoindirubin is depicted in Fig. 2 .
Crystal Structure of (2'Z)-5-Acetamidoindirubin
Crystal and experimental data are given in Table 1 . All of the data were collected with an R-Axis Rapid Rigaku MSC diffractometer using Cu Ka radiation and a graphite monochromator. All reflections were used for unit-cell refinement. The structures were solved by direct methods using Shelx 97 suite of programs, 7 and the positions of the H atoms were deduced from coordinates of the non-H atoms and confirmed by Fourier synthesis. The non-H atoms were refined with anisotropic temperature parameters. H atoms were included for structure factor calculations, but not refined.
The 3D structure of this 5-acetamidoindirubin confirmed the (Z)-configuration in the solid state.
The (Z) C(8)-C(11) double bond was noticed at 1.348(4)Å, as typically observed for C=C substituted indirubin double bonds. 8, 9 C-C distances within the six-membered rings are in the range of 1.368 to 1.394 Å, consistent with the aromatic character of the ring system. The double bonds C(9)=O(10) and C(12)=O (16) (Table 2 ). There are no solvent accessible voids in the crystal lattice of 5-acetamidoindirubin. Crystal cohesion is ensured by a threedimensional netwok of van der Waals and stacking interactions, and by hydrogen bonds. Fig. 2 ORTEP view of the crystal structure of (2'Z)-5-acetamidoindirubin with our numbering scheme. Displacement ellipsoids are drawn at the 30% probability level. 
